González EIR, Cruz EM, Castro PA, Acosta PLE, Sánchez SS, Ruiz IGA, Quesnel SAJ

Language: Spanish
References: 5
Page: 394-396
PDF size: 270.51 Kb.

ABSTRACT

Introduction: fibrolamellar hepatocellular carcinoma (FLC) is a rare form of hepatocellular carcinoma affecting young patients. We present a case of unresectable FLC treated with transarterial chemoembolization and a combination of atezolizumab and bevacizumab. Case description: a 20-year-old woman with abdominal pain, nausea, and vomiting was diagnosed with well-differentiated FLC. A dual therapy regimen was implemented, achieving a 26.7% reduction in lesion size, maintained for 18.13 months. The overall survival was 22.23 months. Conclusion: FLC differs from conventional hepatocellular carcinoma and presents therapeutic challenges. The combination of chemoembolization and immunotherapy shows promising potential. This case adds valuable information about FLC in our country.

REFERENCES

1. Abdelhamed W, El-Kassas M. Fibrolamellar hepatocellular carcinoma: a rare but unpleasant event. World J Gastrointest Oncol. 2022; 14 (6): 1103-1114.

2. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980; 46 (2): 372-379.

3. Lin CC, Yang HM. Fibrolamellar Carcinoma: a concise review. Arch Pathol Lab Med. 2018; 142 (9): 1141-145.

4. Bauer J, Kohler N, Maringer Y, Bucher P, Bilich T, Zwick M et al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun. 2022; 13 (1): 6401.

5. Bernon MM, Gandhi K, Allam H, Singh S, Kloppers J, Jonas E. Trans-arterial therapy for fibrolamellar carcinoma: a case report and literature review. Int J Surg Case Rep. 2022; 94: 106980.